DIVO vs XBI
Amplify CWP Enhanced Dividend Income ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.56% for DIVO.
- • DIVO pays a higher dividend yield (5.07%).
Side-by-side metrics
| Metric | DIVO | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.56% | 0.35% |
Dividend yield Trailing 12-month yield. | 5.07% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $6.97B | $8.30B |
YTD return | 4.40% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.58 | 1.09 |
P/E ratio | 24.34 | — |
Last price | $45.46 | $133.66 |
Inception | — | — |
Issuer | Amplify | State Street |
DIVO top holdings
| CAT | Caterpillar Inc | 6.20% |
| MSFT | Microsoft Corp | 5.49% |
| AAPL | Apple Inc | 5.08% |
| AXP | American Express Co | 5.07% |
| JPM | JPMorgan Chase & Co | 4.92% |
| GS | The Goldman Sachs Group Inc | 4.88% |
| TJX | TJX Companies Inc | 4.73% |
| RTX | RTX Corp | 4.72% |
| SOFR | Amplify Samsung SOFR ETF | 4.30% |
| V | Visa Inc Class A | 4.28% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About DIVO
DIVO (Amplify CWP Enhanced Dividend Income ETF) is Quality dividend payers with tactical covered calls. Managed by Amplify, the fund carries $7.0B in assets under management, an expense ratio of 0.56%, a dividend yield of 5.07%. Its largest holding is Caterpillar Inc (CAT), which represents 6.2% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 13.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.